Trial
NCT01442714
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Stanford University
Collaborators
Celgene Corporation
Condition
Leukemia
Intervention
Azacitidine
Why stopped
Lack of efficacy - Inability to meet the primary response endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-03